Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile

Journal of Medicinal Chemistry
B K TrivediD R Hill

Abstract

We have previously described the design and development of CI-988, a peptoid analogue of CCK-4 with excellent binding affinity and selectivity for the CCK-B receptor. Due to its anxiolytic profile in animal models of anxiety, this compound was developed as a clinical candidate. However, during its development, it was determined that CI-988 had low bioavailability in both rodent and nonrodent species. In the clinic, it was further established that CI-988 had poor bioavailability. Thus, there was a need to identify an analogue with an improved pharmacokinetic (PK) profile. The poor bioavailability was attributed to poor absorption and efficient hepatic extraction. We envisaged that reducing the molecular weight of the parent compound (5, MW = 614) would lead to better absorption. Thus, we synthesized a series of analogues in which the key alpha-methyltryptophan and adamantyloxycarbonyl moieties, required for receptor binding, were kept intact and the C-terminus was extensively modified. This SAR study led to the identification of tricyclo[3.3.1.1(3,7)]dec-2-yl [1S-[1 alpha(S*)2 beta]-[2-[(2-hydroxycyclohexyl)amino]-1-(1H-indol-3- ylmethyl)-1-methyl-2-oxoethyl]carbamate (CI-1015, 31) with binding affinities of 3.0 and 2900 nM for ...Continue Reading

References

Sep 1, 1991·British Journal of Pharmacology·L SinghG N Woodruff
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J HughesG N Woodruff
Jul 1, 1987·Journal of Medicinal Chemistry·B E EvansD F Veber

❮ Previous
Next ❯

Citations

Jun 15, 1999·Progress in Neurobiology·F Noble, B P Roques
Feb 26, 2013·Chemical Reviews·Lukas WankaPeter R Schreiner
Jul 27, 1999·Current Opinion in Chemical Biology·R M Freidinger
Sep 6, 2002·Journal of Peptide Science : an Official Publication of the European Peptide Society·Dirk WeberHorst Kessler
Jun 6, 2003·Medicinal Research Reviews·Rosario Herranz
Apr 4, 2015·Public Understanding of Science·Annamaria Lusardi
Nov 17, 2001·Chemical Reviews·F Fülöp
Oct 6, 2000·Journal of Medicinal Chemistry·M Martín-MartínezR González-Muñiz
May 2, 2003·Journal of Medicinal Chemistry·Dirk WeberHorst Kessler
May 23, 2020·Drug Discovery Today·Doroteja NovakPetra Kolenc Peitl
Dec 22, 2006·Journal of Medicinal Chemistry·Stephen A Hitchcock, Lewis D Pennington
Nov 24, 2005·Journal of Medicinal Chemistry·Mercedes Martín-MartínezRosario González-Muñiz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.